scholarly journals Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis

1993 ◽  
Vol 36 (9) ◽  
pp. 1286-1294 ◽  
Author(s):  
Niall E. Roche ◽  
James W. Fulbright ◽  
Annette D. Wagner ◽  
Gene G. Hunder ◽  
Jörg J. Goronzy ◽  
...  
Keyword(s):  
Disease Activity ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Interleukin 6 ◽  
Polymyalgia Rheumatica

scholarly journals Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica

Rheumatology ◽  
2015 ◽  
Vol 54 (8) ◽  
pp. 1397-1402 ◽  
Author(s):  
Kornelis S. M. van der Geest ◽  
Wayel H. Abdulahad ◽  
Abraham Rutgers ◽  
Gerda Horst ◽  
Johan Bijzet ◽  
...  
Keyword(s):  
Disease Activity ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Polymyalgia Rheumatica ◽  
Serum Markers

scholarly journals Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?

RMD Open ◽  
2016 ◽  
Vol 2 (2) ◽  
pp. e000305 ◽  
Author(s):  
Éric Toussirot ◽  
Alexis Régent ◽  
Valérie Devauchelle-Pensec ◽  
Alain Saraux ◽  
Xavier Puéchal
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Interleukin 6 ◽  
Polymyalgia Rheumatica ◽  
Promising Target

scholarly journals Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity

2000 ◽  
Vol 43 (5) ◽  
pp. 1041 ◽  
Author(s):  
Cornelia M. Weyand ◽  
James W. Fulbright ◽  
Gene G. Hunder ◽  
Jonathan M. Evans ◽  
Jörg J. Goronzy
Keyword(s):  
Disease Activity ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Interleukin 6 ◽  
Biologic Marker

scholarly journals AB0460 INTERLEUKIN-6 INHIBITION WITH TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA IN PATIENTS WITH SERIOUS COMORBIDITIES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1528.1-1529
Author(s):  
T. Beketova ◽  
E. Otteva ◽  
E. Nasonov
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Interleukin 6 ◽  
Polymyalgia Rheumatica ◽  
Rapid Improvement ◽  
Inflammatory Conditions ◽  
Optimal Dosing ◽  
Olecranon Bursitis ◽  
Ischemic Complications ◽  
Artery Disease

Background:Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely related inflammatory conditions affecting people aged over 50 years.Objectives:We present our experience of using tocilizumab (TCZ) therapy for management of GCA/PMR aggravated by severe concurrent pathologies that potentially increase the risk of side effects of glucocorticoids (GCs).Methods:22 patients were recruited into the prospective study: six patients with GCA, 13- PMR, and three- with both GCA and PMR, 95.5% were females, mean age 72.8±6.5 years. Mean disease duration was 3.5 (0.5-19) months. All patients had active GCA/PMR with mean CRP 30.3±32.7 mg/l. Seven patients had visual ischemic complications, and another one- aortitis. All patients had serious comorbidities, 59% of patients had three and more severe concurrent diseases. All patients were administered TCZ i/v 2.3-8.8 mg/kg Q4W. 50% patients were also treated with prednisone at mean 20 (10-70) mg/day. The follow-up period was 24 (6-60) months.Results:All patients demonstrated good clinical response to TCZ i/v 2.3-8.8 mg/kg Q4W given for average 4,5 (2-11) months, achieving remission in 100% of cases. Some patients showed a very rapid improvement after initiation of treatment, including TCZ monotherapy. Prednisone dose was discontinued in 6/11, or was reduced to 2.5 (2.5-10) mg in 4/11. There was one relapse after TCZ discontinuation, although this patient managed to regain the remission after resumption of TCZ i/v 4 mg/kg. There was one (4.6%) serious complication (septic olecranon bursitis 1 month after TCZ discontinuation), one patient died of myocardial infarction 12 months later after TCZ discontinuation. Three remaining complications included one case of peripheral artery disease (claudication), one- psoriasis, and one- sural lipodermatosclerosis.Conclusion:Interleukin-6 inhibitors should be considered as potentially effective and relatively safe treatment for GCA/PMR patients with serious comorbidities, intolerance or contraindications to standard therapy. More data is necessary to identify the optimal dosing regimen and duration of TCZ therapy, as well as cost-effectiveness aspects.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document